1️⃣ Objective: To assess GPT-4's capability in answering clinically relevant questions based on ASCO and ESMO guidelines. 2️⃣ Method: GPT-4 responses were evaluated with and without retrieval-augmented generation (RAG). GPT-4 with RAG showed significantly higher accuracy. 3️⃣ Findings: GPT-4 with RAG provided 84% correct responses, whereas GPT-4 without RAG provided only 57% correct responses. 4️⃣ Guideline Comparisons: Key differences in recommendations for pancreatic, colorectal, and hepatocellular cancers were identified. For instance, ESMO uniquely proposed liver transplantation for certain colorectal cancer cases, and ASCO discussed socioeconomic factors affecting patient outcomes. 5️⃣ Performance Metrics: The study used faithfulness and relevance metrics for automated evaluation, supplemented by manual reviews from oncology experts. 6️⃣ Error Analysis: Among the incorrect responses, 4 were considered medically relevant due to factual misinformation, highlighting areas for model improvement.
Curei.ai’s Post
More Relevant Posts
-
Asset assessment for in licensing and out licensing, R&D, US FDA IND Regulatory Submission for BTD/ODD/AA, Global/local Clinical Studies, Board of Directors, International Speaker, CDP, M&A, Hiring, CME advice, Editor.
Systemic chemotherapy is the standard treatment for unresectable BTC. However, clinical trials have failed to take the heterogeneity of BTC into account. Gemcitabine plus cisplatin achieved significant survival advantage over gemcitabine monotherapy in ABC-02 trial and became the standard of care for first-line treatment in unresectable BTC [4]. In Japan, gemcitabine plus S-1 and gemcitabine, cisplatin plus S-1 triplet therapy have shown efficacy and are also considered options for first-line treatment [5,6]. Nanoliposomal irinotecan plus fluorouracil and leucovorin recently showed efficacy comparable to gemcitabine and cisplatin in a randomized phase II trial [7]. The superiority of triplet therapy consisting of gemcitabine plus cisplatin (GC) and immune checkpoint inhibitors durvalumab or pembrolizumab was shown in the TOPAZ-1 and KEYNOTE-966 trials, respectively, heralding a new era of immunotherapy in BTC [8,9]. The median overall survival (OS) achieved 12.7–12.8 months with triplet therapy consisting of GC and immune checkpoint inhibitors. #Biliarycancer #Gastroenterology #Oncology
-
Telix’s Phase III ZIRCON trial of TLX250-CDx ([⁸⁹Zr]girentuximab) has been published in The Lancet Oncology In this first peer-reviewed manuscript, Prof. Brian Shuch and colleagues report that “[⁸⁹Zr]girentuximab PET–CT is a highly accurate, non-invasive imaging modality for the detection and characterisation of clear-cell renal cell carcinoma (ccRCC)”. For detection of ccRCC in patients with an indeterminate renal mass (IRM) ≤7 cm, authors report that [⁸⁹Zr]girentuximab PET–CT had a mean sensitivity and specificity of 86% and 87%, respectively, and positive predictive value of 93%. Diagnostic performance was consistent in patients irrespective of smaller size IRMs (≤4 cm, ≤3 cm, and ≤2 cm). Authors conclude that “PET–CT imaging accurately identified ccRCC in patients with cT1 indeterminate renal masses (≤7 cm), with a favourable safety profile. These results establish the value of [⁸⁹Zr]girentuximab PET–CT imaging as a new standard, non-invasive tool for the diagnosis and detection, characterisation and differentiation of ccRCC from other renal and extrarenal lesions in clinical practice, minimising the risk of unnecessary invasive interventions.” To read more, including the full article, visit our website here: https://lnkd.in/g8hVCsNN
-
#SolidTumor trials require #Imaging professionals immersed in the scientific advances & regulatory changes that may impact your #ClinicalDevelopment program. Learn how the therapeutic, modality, and regulatory expertise of your #MedicalImaging provider can make or break your #Antitumor trial. https://lnkd.in/gtUiMfMX #ChooseCalyx #ClinicalTrials #Oncology
Imaging in Solid Tumor Trials: Many Changes Can Impact Success | Calyx
https://www.calyx.ai
-
#Webinar now available on demand! Assessing #CARTcelltherapy #invitro using patient-derived #glioblastomaorganoids While CAR-T cell therapies have shown great promise against hematological cancers, their success in solid tumors has been limited. Patient-derived #tumororganoids may better recapitulate solid tumor biology and serve as a promising model for exploring the effects of new therapeutics in vitro. FDA-NIH’s Meghan Logun (Regulatory Oncology Product Reviewer, Interagency Oncology Task Force) explores early efficacy signals recently demonstrated in a first-in-human, phase 1 study of dual-targeting CAR-T cells in patients with recurrent glioblastoma. Watch at your convenience below:
Assessing CAR-T cell therapy <em>in vitro</em> using patient-derived glioblastoma organoids
insights.bio
-
Burning Rock Dx Spotlight: OnconCompass®Target The study published in Journal of Thoracic Oncology at Feb. 2020, aimed to assess the impact of harboring 5′-ALK on the efficacy of crizotinib. The study is the first to confirm that presence of nonreciprocal/reciprocal ALK translocation was predictive for worse PFS and greater likelihood of baseline brain metastases in patients with ALK-rearranged NSCLC who received first-line crizotinib. This study uses OnconCompass®Target to sequence DNA isolated from tissue or blood samples obtained from all the patients. 🔗 Read more: https:https://lnkd.in/gZW3247E #NSCLC #BurningRockDx
Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC
jto.org
-
The landscape of lymphoma treatment is evolving with the integration of advanced imaging biomarkers, enhancing how we assess therapy responses. Lymphomas, including non-Hodgkin and Hodgkin types, are significant blood cancers with increasing incidence globally. Traditional size-based imaging methods often fall short in evaluating treatment efficacy, prompting a shift towards more sophisticated imaging techniques. Functional imaging, particularly 18F-FDG PET/CT, is revolutionizing our approach. By measuring metabolic activity rather than just size, it provides deeper insights into tumor response assessments. With superior sensitivity and specificity compared to traditional CT, methods like the Deauville 5-point scale in Lugano criteria are improving patient management decisions. Furthermore, innovative approaches like DWI and PET/MRI are paving the way for more accurate assessments of nodal involvement and tumor microenvironments. Bone marrow biopsies continue to play a crucial role alongside advanced imaging when it comes to response assessments. Clinical trials utilizing PET/CT are critical for standardizing response criteria and enhancing treatment evaluations. IE recently published a white paper entitled "Optimizing Imaging Response Criteria for Improved Outcomes in Oncology Clinical Trials ," available online at: https://hubs.li/Q02Z0-6M0 which frames and highlights IE's unparalleled approach to image analysis customization and optimization, including clarifications and modifications to applicable criteria like Lugano. Our physicians and operations experts, including our Chief Medical Officer Dr. Korn, are available to meet at ASH 2024 to discuss how we can leverage our experience and expertise to support your upcoming trials. Reserve your time here. https://hubs.li/Q02Z0SH40 #Lymphoma #ImagingBiomarkers #PETCT #ImagingEndpoints #ClinicalTrials #MedicalImaging #Oncology #ASH2024
Optimizing Imaging Response Criteria for Improved Outcomes in Oncology Clinical Trials
fiercepharma.com
-
📣 We recently contributed to some important T cell therapy research! https://bit.ly/3NaQWqe The study aimed to determine eligibility for TCR T cell therapies based on HLA typing and MAGE-A4 testing. Our team optimized, validated, and performed the MAGE-A4 assay, generated the whole-slide images and provided extensive pathology interpretation. The study's key findings were: ⭐ 45% of screened patients were HLA eligible, varying by race and ethnicity ⭐ 26% of screened tumour tissue was MAGE-A4 positive, which varied by cancer type ⭐ Accuracy evaluations of the HLA typing assay and the MAGE-A4 IHC assay indicated they are reliable when assessing patient eligibility for TCR T cell therapy clinical trials T cell therapies represent a way to overcome limitations of other adoptive cell therapies, such as narrow applicability. This study sets a foundation on the importance of biomarker screening for TCR T cell therapies, paving the way for future research. #PrecisionMedicine #CellTherapy #Biomarkers #CellCarta
-
-
Join us on September 17, 2024, from 10-11 AM EST for an insightful webinar with Dr. Andrew Satterlee, as he discusses the cutting-edge advancements in functional drug screening of patient tumor tissues. Learn how his innovative ex vivo platform is transforming cancer treatment by accelerating pre-clinical drug testing and providing actionable insights for personalized medicine. Save the date and register for free: https://lnkd.in/eV6R5G57 Don’t miss this opportunity to explore how these technologies are shaping the future of oncology research! #CancerResearch #PrecisionMedicine #PrecisionaryInstruments #compresstome #microtomes #vibratingmicrotomes #vibratomes #tissuesectioning #precisioncuttissuesslices #tissueslicing #laboratoryequipment #labsolutions
A Living Ex Vivo Platform for Functional Drug Screening of Patient Tumor Tissues
docs.google.com
-
📄 [Press release] – MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT 🩸 Key highlights: ✅ DSMB recommends proceeding as planned without modifications ✅ MaaT033 has shown to have an acceptable safety profile and was well tolerated in patients treated for blood cancers and receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). 🦠Phase 2b trial PHOEBUS, the largest one to date for a microbiome therapy in oncology, is an international, multi-center, randomized, double-blind, testing MaaT033, an oral freeze-dried formulation against placebo. https://lnkd.in/emffi3dR #Microbiome #BloodCancer #Cancer #DSMB #Safety
-
President, Chief Executive Officer, and Board Director at Candel Therapeutics ($CADL) & Former Senior Vice President, Chief Immunology Officer, and Global Development Leader at GSK
The transformative potential of Candel Therapeutics' therapeutic approach was spotlighted at the 16th Annual International Oncolytic Virus Conference. The presentations showcased the company's progress in developing new therapies and translating groundbreaking discoveries into potential clinical candidates. Excitingly, encouraging overall survival data post CAN-3110 experimental treatment in recurrent glioblastoma hints at a prolonged survival tail, akin to observations with immunotherapies in other solid tumors. Notably, post-CAN-3110 administration, tumor biopsies revealed a scarcity of tumor cells alongside dense lymphocyte infiltrates, particularly in patients with enhancement on post-treatment MRI scans (pseudo-progression). #CandelTherapeutics #viral #immunotherapy #CAN-3110 #glioblastoma #braintumor $CADL Read more: [Candel Therapeutics Showcase at IOVC](https://lnkd.in/e4K4R_7G)
